Log in with your email address username.


[Correspondence] Dual antiplatelet therapy duration and mortality

We read with great interest the Review and meta-analysis by Sammy Elmariah and colleagues (Feb 28, p 792),1 in which they suggest that prolonged duration dual antiplatelet therapy (DAPT) is not associated with a difference in the risk of cardiovascular or non-cardiovascular death, compared with aspirin alone or short duration DAPT. In contrast, results of the 2014 DAPT Study by Laura Mauri and colleagues2 showed that continuation of DAPT beyond 12 months after coronary stenting was associated with an increase in the risk of non-cardiovascular death.